Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Daytraders  /  PTX kocht ik 3-7 op $ 4,53 waarna hij fors daalde.

Ontvang nu dagelijks onze kooptips!

word abonnee

Daytraders« Terug naar discussie overzicht

PTX kocht ik 3-7 op $ 4,53 waarna hij fors daalde.

9 Posts
| Omlaag ↓
  5. [verwijderd] 2 september 2016 14:16
    Ik ben bang dat ze nog wel ff laag blijven of zelfs verder zakken. Ze verkopen voor veel miljoenen minder en de kosten stijgen met miljoenen.
    Denk dat ze betere verkopers nodig hebben of nieuwe verbeterde producten.

    Treximet net sales decreased by $12.4 million, or 27%, during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. Silenor net sales decreased by $3.2 million, or 29%, during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. The decrease in sales of Treximet and Silenor was primarily driven by a decrease in sales volume and higher revenue deductions for managed care rebates. Zohydro ER net sales increased $7.4 million, or 185%. This increase was due to an increase in demand, as well as the impact of a full six months of sales in the period ended June 30, 2016 compared to two months of sales in the prior year period when Zohydro ER was acquired. Sales of Other net product sales decreased by $3.2 million, or 17%, during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. This decrease was due primarily to the discontinuation of certain less profitable products, primarily generics, and certain OTC monograph seasonal cough and cold products.

    Gross Margin decreased to 66% in the six months ended June 30, 2016 from 69% in the six months ended June 30, 2015. This was due primarily to a contractual minimum royalty incurred for sales of Treximet.

    Selling, general and administrative expense increased by $5.6 million, or 12%, during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. The increase was driven primarily by selling and marketing costs for Zohydro ER with BeadTek, which was acquired in April 2015.

    Research and development expense increased by $1.0 million during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. The increase was related to the timing of on-going work for Treximet and Zohydro ER.

    Depreciation and amortization expense increased by $4.0 million during the six months ended June 30, 2016 compared to the six months ended June 30, 2015. The increase was primarily a result of the amortization of Treximet pediatrics developed technology, which began in May 2015, and amortization related to the acquisition of Zohydro ER with BeadTek in April 2015. The increase was partially offset by an extension of the estimated useful life of Zohydro ER with BeadTek during the three months ended March 31, 2016, and intangible asset impairments during the six months ended June 30, 2016 and the year ended December 31, 2015.

    Interest expense decreased by $1.2 million, or 6%, during the six months ended June 30, 2016 compared to the prior year period. The decrease was primarily due to the lower principal balance on our Treximet Secured Notes.

    Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, a non-GAAP measure) was ($5.9) million for the six month period of 2016 compared to $12.5 million in the same period of 2015. See the table at the end of this press release for a reconciliation of net loss to Adjusted EBITDA.
9 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 912,70 +0,23%
EUR/USD 1,0776 +0,04%
FTSE 100 8.443,31 +0,11%
Germany40^ 18.765,60 -0,04%
Gold spot 2.350,34 -0,44%
NY-Nasdaq Composite 16.340,87 -0,03%

Stijgers

EBUSCO...
+3,28%
Akzo N...
+2,47%
ABN AM...
+1,48%
JDE PE...
+1,34%
Air Fr...
+1,33%

Dalers

FASTNED
-1,07%
AZERION
-1,03%
Pharming
-1,02%
Kendrion
-0,92%
Avantium
-0,74%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!